Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine if CIC 50 mg/day or 200 mg/day (ex-valve) administered
once daily in the morning is non-inferior to placebo with respect to growth velocity in
children with mild persistent asthma following a 12-month treatment period
The secondary objective is to investigate changes in growth in terms of bone age (wrist
X-ray), and maintenance of asthma control and safety with ciclesonide